TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate
Abstract Background Germline heterozygous pathogenic variants (PVs) in TP53 cause Li-Fraumeni syndrome (LFS), a condition associated with increased risk of multiple tumor types. As the associated cancer risks were refined over time, clinical criteria also evolved to optimize diagnostic yield. The im...
Saved in:
Main Authors: | Paula Rofes, Carmen Castillo-Manzano, Mireia Menéndez, Álex Teulé, Sílvia Iglesias, Elisabet Munté, Mireia Ramos-Muntada, Carolina Gómez, Eva Tornero, Esther Darder, Eva Montes, Laura Valle, Gabriel Capellá, Marta Pineda, Joan Brunet, Lidia Feliubadaló, Jesús del Valle, Conxi Lázaro |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Genome Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13073-025-01429-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Personalized screening strategies for TP53 R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriersResearch in context
by: Pedro A.F. Galante, et al.
Published: (2025-02-01) -
A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer
by: Bohao Zhang, et al.
Published: (2025-01-01) -
Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer
by: Zihua Zou, et al.
Published: (2025-01-01) -
TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis
by: Jin Li, et al.
Published: (2025-01-01) -
Unveiling the prognostic value of ARID3A in breast cancer through bioinformatic analysis
by: Wen-Run Cai, et al.
Published: (2025-02-01)